The global single dose radiotherapy services market is expected to attain a valuation of US$ 7.88 billion in 2023 and is projected to reach US$ 16 billion by 2033, expanding at a CAGR of 7.3% during the forecast period.
Single Dose Radiotherapy is gaining popularity for the treatment of breast cancer and prostate cancer due to several advantages it offers. This advanced approach provides high precision, ensuring accurate targeting of cancer cells while maximizing patient comfort. It is additionally known for its cost-effectiveness and ability to produce favorable cosmetic outcomes.
The combination of its precision, patient comfort, cost-effectiveness, and improved cosmetic results has driven the growing adoption of single-dose radiotherapy services specifically for breast cancer and prostate cancer.
The global incidence of oncology diseases like prostate cancer, lung cancer, and breast cancer is on the rise, leading to a growing need for prompt and effective management to mitigate mortality rates. This significant trend is driving the expansion of the single dose radiotherapy market. For example, Breastcancer.org reported that in March 2022, approximately 287,850 new cases of invasive breast cancer and 51,400 new cases of non-invasive (in situ) breast cancer are projected to be diagnosed among women in the United States.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 7.88 billion |
| Anticipated Forecast Value (2033) | US$ 16 billion |
| Projected Growth Rate (2023 to 2033) | CAGR 7.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The single dose radiotherapy services market was worth US$ 4.6 billion in 2017. It accumulated a market value of US$ 6.1 billion in 2022 while growing at a CAGR of 5.8% during the historical period.
Breast cancer, a progressive illness, affects over 2 million individuals globally and has a substantial impact on female mortality rates. Likewise, prostate cancer diagnoses exceed 1.4 million in men aged 45 years and above worldwide. The increasing occurrence of breast and prostate cancer has driven the expansion of the single-dose radiotherapy services market.
In the past, the limited availability of clinical data on single-dose radiotherapy hindered its widespread use in treating early-stage breast and prostate cancer. However, the current landscape is witnessing numerous ongoing clinical trials aimed at demonstrating the effectiveness and safety of single-dose radiotherapy in early-stage cancer treatment. These trials are paving the way for broader adoption by radiologists, as it holds the potential to reduce the time and costs associated with multiple fraction radiotherapy.
An example of pioneering work in the field is being conducted by the oncologists at the TARGIT Collaborative Group (TCG), who are actively engaged in the advancement of a groundbreaking form of single-dose radiotherapy called TARGIT-IORT. According to their research, TARGIT-IORT involves the precise administration of targeted radiation directly to the breast during surgery, shortly after tumor removal. Remarkably, 8 out of 10 patients who received TARGIT-IORT immediately following lumpectomy did not require any further radiotherapy treatments after this combined procedure. The market is projected to be worth US$ 16 billion by the end of forecast period while exhibiting a CAGR of 7.3%.
Adoption of External Beam Radiation Therapy to fuel Market Growth
The demand for radiotherapy has significantly risen in recent years due to various factors. These include a growing number of cancer patients, a rise in the geriatric population, greater adoption of radiotherapy devices and procedures, an increase in awareness campaigns promoting the benefits of radiotherapy, and advances in radiotherapy technology.
The adoption of external-beam radiation therapy has surged significantly, driven by its effectiveness in treating a broad range of cancers, including lung, prostate, breast, colorectal, liver, thyroid, lymphoma, brain, and spine cancer. This type of radiation therapy is highly favored and widely used in cancer treatment. It involves directing high-energy rays toward the tumor from outside the body, which has propelled its popularity and contributed to market growth.
The presence of reimbursement policies is expected to create numerous market opportunities for industry expansion. Various reimbursement policies associated with brachytherapy products have led to reduced treatment costs, incentivizing patients to seek treatment. For example, Isoray's announcement of approved billing codes for Cesium-131 reimbursement in hospital DRG sets in 2020 has accelerated market growth significantly. This factor plays a crucial role in driving rapid market expansion.
Principal Consultant
Lack of Skilled Professionals to Restrain Market Expansion
The lack of skilled professionals and a lack of technical expertise is expected to restrain market growth. The shortage of oncologists in the United States is a significant concern, with American Society of Clinical Oncology (ASCO) projecting a deficit of over 2,200 oncologists by 2025. Consequently, these factors act as obstacles to the expansion of the market.
North America Driving Growth with Significant CAGR
The North American single dose radiotherapy services market accounted for a revenue share of 41% in 2022. The demand outlook for single dose radiotherapy services treatment in the region is expected to grow with a CAGR of 7.1% during the forecast period.
The United States healthcare system is renowned for its advanced infrastructure and high expenditures. Cancer care centers and hospitals adhere to regulatory guidelines and insurance policies in their treatment protocols. The substantial hospital bills, apart from those covered by Medicare, contribute to the growth of the market in the country.
The United States government and regulatory authorities are actively implementing cost-containment plans to alleviate the healthcare burden. In addition, they are taking proactive initiatives to promote research activities focused on the development and treatment plans for single-dose radiotherapy in cancer care.
As an example, in 2019, the American Cancer Society provided over $67 million in funding for breast cancer research via 162 research and training grants. Moreover, the American Cancer Society Cancer Action Network (ACS CAN) augmented the funding for the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) at both state and federal levels.
The United States witnesses a higher prevalence of breast cancer and prostate cancer, prompting numerous service providers to initiate awareness campaigns to educate the public about these diseases. This increased awareness is expected to positively impact the overall market growth in the country.
China to emerge as an important Player in the Single Dose Radiotherapy Services Domain
The market in East Asia is expected to grow with a CAGR of 7.4% throughout the forecast period. The market in China is projected to grow at a CAGR of 7.5% during the forecast period.
South Asia is poised for accelerated growth in the coming years. According to the World Health Organization, there has been an upward trend in the incidence rate of "westernized lifestyle-related cancer," including prostate cancer in males, as well as obesity and hormonal exposure-related cancers such as breast cancer in females, reported in China in 2018.
In China, a comprehensive nationwide survey conducted in 2018 indicated that approximately 13.8% of females were affected by breast cancer, while 19.25% of males were diagnosed with prostate cancer. Additionally, according to the Global Burden of Disease Study, both breast cancer and prostate cancer emerged as the leading causes of death among the top five types of cancer in the country in 2018.
These statistics reflect significant opportunities for expanded penetration in China, thereby extending to South Asia. The increasing incidence of breast cancer and prostate cancer in China serves as a crucial driver for rapid growth of the market in the region.
A rise in government spending on healthcare, increasing funding for cancer research, and growing prevalence of cancer is expected to propel market growth in the region. Additionally, government initiatives toward strengthening healthcare facilities and increasing health insurance penetration are further fuelling the demand for single dose radiotherapy services.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
External Beam Radiotherapy Leading the Market
The external beam radiotherapy segment is expected to lead the single dose radiotherapy services market. This segment is expected to flourish at a CAGR of 7.9% throughout the forecast period.
The growth of the market is primarily attributed to the remarkable precision achieved through external beam therapy. Advancements in this therapy enable the delivery of higher and more precise radiation doses while minimizing harm to healthy tissues. Additionally, patients who are deemed unfit for surgery, further driving its popularity in the market, prefer external radiotherapy.
External beam radiotherapy is a commonly utilized treatment approach for breast cancer and prostate cancer. Its ease of operation and non-invasive nature make it a preferred choice among physicians. While external beam radiotherapy can be costly, many service providers offer reimbursement options for these procedures. Interestingly, the cost of a single dose of external beam radiotherapy is typically higher for prostate cancer patients compared to breast cancer patients, resulting in higher revenue within the single-dose radiotherapy services market.
Prostate Cancer Indication to account for maximum deployment
The prostate cancer segment is expected to account for a sizeable share by end of the forecast period. The segment is expected to grow with a CAGR of 8% during the forecast period.
The growth of this segment can be attributed to the significant incidence of prostate cancer and its relatively high success rate compared to other types of cancer. For example, data from GLOBOCAN indicates that there were 1.4 million reported cases of prostate cancer in 2020, with an expected increase to 1.9 million cases by 2040. This sustained rise in cases contributes to the segment growth as well as the overall growth of the market.
Start-ups are crucial in identifying growth opportunities, including the single-dose radiotherapy services market. They efficiently convert inputs to outputs and adapt to market changes, contributing to the industry's expansion. Some start-ups are expected to drive growth in the single-dose radiotherapy services market.
The single dose radiotherapy services market is highly competitive, with several key industry players investing heavily in the production of these services. The key industry players are Accuray Incorporated, Varian Medical Systems, Inc., Elekta AB, ViewRay, Inc., IBA Worldwide, Alliance Oncology, GenesisCare, Hitachi, Ltd., RaySearch Laboratories AB, and Provision Healthcare.
Key industry players leverage organic growth strategies like acquisition, mergers, partnerships, and collaboration to enhance their product portfolio. This is expected to fuel the global single dose radiotherapy services market.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 7.88 billion |
| Market Value in 2033 | US$ 16 billion |
| Growth Rate | CAGR of 7.3% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization & Pricing | Available Upon Request |
The market is estimated to secure a valuation of US$ 7.88 billion in 2023.
The market is estimated to US$ 16 billion by 2033.
Through 2033, the market is anticipated to expand at a 7.3% CAGR.
The market in China is set to progress at a CAGR of 7.5%.
The North American market makes up 41% of total revenue.
External beam radiotherapy segment is experiencing significant growth in the industry, with a CAGR of 6.9%.
The prostate cancer segment is to thrive at a CAGR of 8%.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2017 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
5.3.1. Breast Cancer
5.3.2. Prostate Cancer
5.4. Y-o-Y Growth Trend Analysis By Indication, 2017 to 2022
5.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Therapy
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2017 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033
6.3.1. External Beam Radiotherapy
6.3.2. Internal Beam Radiotherapy
6.4. Y-o-Y Growth Trend Analysis By Therapy, 2017 to 2022
6.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Service Provider
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Service Provider, 2017 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Service Provider, 2023 to 2033
7.3.1. Hospitals
7.3.2. Radiotherapy Centers
7.3.3. Specialized Cancer Institutes
7.4. Y-o-Y Growth Trend Analysis By Service Provider, 2017 to 2022
7.5. Absolute $ Opportunity Analysis By Service Provider, 2023 to 2033
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Indication
9.2.3. By Therapy
9.2.4. By Service Provider
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Indication
9.3.3. By Therapy
9.3.4. By Service Provider
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Indication
10.2.3. By Therapy
10.2.4. By Service Provider
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Indication
10.3.3. By Therapy
10.3.4. By Service Provider
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Indication
11.2.3. By Therapy
11.2.4. By Service Provider
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Indication
11.3.3. By Therapy
11.3.4. By Service Provider
11.4. Key Takeaways
12. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Indication
12.2.3. By Therapy
12.2.4. By Service Provider
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Indication
12.3.3. By Therapy
12.3.4. By Service Provider
12.4. Key Takeaways
13. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Indication
13.2.3. By Therapy
13.2.4. By Service Provider
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Indication
13.3.3. By Therapy
13.3.4. By Service Provider
13.4. Key Takeaways
14. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Indication
14.2.3. By Therapy
14.2.4. By Service Provider
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Indication
14.3.3. By Therapy
14.3.4. By Service Provider
14.4. Key Takeaways
15. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Indication
15.2.3. By Therapy
15.2.4. By Service Provider
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Indication
15.3.3. By Therapy
15.3.4. By Service Provider
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Indication
16.1.2.2. By Therapy
16.1.2.3. By Service Provider
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Indication
16.2.2.2. By Therapy
16.2.2.3. By Service Provider
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Indication
16.3.2.2. By Therapy
16.3.2.3. By Service Provider
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Indication
16.4.2.2. By Therapy
16.4.2.3. By Service Provider
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Indication
16.5.2.2. By Therapy
16.5.2.3. By Service Provider
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Indication
16.6.2.2. By Therapy
16.6.2.3. By Service Provider
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Indication
16.7.2.2. By Therapy
16.7.2.3. By Service Provider
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Indication
16.8.2.2. By Therapy
16.8.2.3. By Service Provider
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Indication
16.9.2.2. By Therapy
16.9.2.3. By Service Provider
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Indication
16.10.2.2. By Therapy
16.10.2.3. By Service Provider
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Indication
16.11.2.2. By Therapy
16.11.2.3. By Service Provider
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Indication
16.12.2.2. By Therapy
16.12.2.3. By Service Provider
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Indication
16.13.2.2. By Therapy
16.13.2.3. By Service Provider
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Indication
16.14.2.2. By Therapy
16.14.2.3. By Service Provider
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Indication
16.15.2.2. By Therapy
16.15.2.3. By Service Provider
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Indication
16.16.2.2. By Therapy
16.16.2.3. By Service Provider
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Indication
16.17.2.2. By Therapy
16.17.2.3. By Service Provider
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Indication
16.18.2.2. By Therapy
16.18.2.3. By Service Provider
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Indication
16.19.2.2. By Therapy
16.19.2.3. By Service Provider
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Indication
16.20.2.2. By Therapy
16.20.2.3. By Service Provider
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Indication
16.21.2.2. By Therapy
16.21.2.3. By Service Provider
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Indication
17.3.3. By Therapy
17.3.4. By Service Provider
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Accuray Incorporated
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Varian Medical Systems, Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Elekta AB
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. ViewRay, Inc.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. IBA Worldwide
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Alliance Oncology
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. GenesisCare
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Hitachi, Ltd.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. RaySearch Laboratories AB
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Provision Healthcare
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Healthcare
February 2024
REP-GB-16820
342 pages
Explore Healthcare Insights
View Reports
Single Dose Radiotherapy Services Market
